For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
HOME > ORGANIZATION
ORGANIZATION
- JMA Sets Up “Council on Medical COI” Out of Concerns Over Transparency GL
January 11, 2013
- JPWA Chief Bessho Calls for Clearer Rule for Sales Tax on Ethical Drugs
January 10, 2013
- Efforts to Promote Generic Substitution Preferable to Cutting Prices of Long-Listed Drugs: Mr Sawai of JGA
January 8, 2013
- Member Companies to Begin Enforcing New COP in FY2013: JPMA President Teshirogi
January 7, 2013
- JPMA to Ask Abe Administration to Continue Former Dialogue with Pharmaceutical Industry: Dr Teshirogi
January 7, 2013
- NHO to Review Calculation Method for Clinical Trial Costs
December 28, 2012
- JPA to Hold Workshops to Train Pharmacists to Make Clinical Assessments Based on Subjective Symptoms
December 26, 2012
- JMA to Discuss JPMA’s Transparency Guidelines with JPMA, Related Medical Organizations
December 25, 2012
- “New Administration Needed to Allocate Personnel to Cabinet, LDP to Work Out Challenges”: Keizai Doyukai Chair Hasegawa
December 19, 2012
- Generic Market Share at 25.4% in 2nd Quarter on Volume Basis: JGA
December 14, 2012
- Tohoku Pharmaceutical Univ. to Acquire Tohoku Kosei Nenkin Hospital, Aiming to Turn It into Model Hospital for Pharmaceutical Education
December 14, 2012
- Panelists at IGPA Conference Express Concern that FTA Could Strengthen Intellectual Property Rights
December 10, 2012
- GIST Patients Group Submits Petition Calling for Early Filing for Regorafenib for GIST
December 10, 2012
- Kyoto Declaration Calls for Strict Quality Control of Generics: IGPA Annual Conference
December 10, 2012
- Biosimilars Popular Topic at IGPA Annual Conference
December 10, 2012
- Ways to Deal with Biosimilars Will Be Common Challenge Among Generics Companies: JGA President Sawai
December 6, 2012
- Drug Costs Should Be Basically Borne by Patients under Compassionate Use System: JPMA’s Kuwahara
December 5, 2012
- 80 Medical Institutions Submit Comprehensive Agreements on Info Disclosure in Response to JPMA Transparency GLs
December 4, 2012
- Top Officials of FPMAJ, JGA Disagree on Progress in Generic Drug Use at CSIMC Expert Subcommittee Meeting
November 30, 2012
- Pharmaceutical Makers to Reap Equal Benefits from Premium for New Drug Development in Long Run: FPMAJ Chief Naito
November 29, 2012
ページ
Earlier this month, the Ministry of Finance (MOF) unveiled a long list of social security proposals towards the FY2025 budgeting,…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…